Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response

Trial Profile

Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms PInNACLe
  • Most Recent Events

    • 12 Dec 2017 Results (n=12) assessing the immune effects of nilotinib combined with pegylated-interferon-alpha 2b in a subgroup of newly diagnosed chronic phase chronic myeloid leukemia (CML) patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Protocol-specified interim analysis results (n=33) assesing tolerability of the combination and efficacy as measured by molecular responses presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top